Efficacy and safety of inhalation 6% N-acetylcysteine in 3% NaCl solution in clinical practice (literature review)
DOI:
https://doi.org/10.15574/SP.2022.126.120Keywords:
N-acetylcysteine, treatment, inhalationAbstract
The article summarizes the literature on the use of N-acetylcysteine and its combination with 3% NaCl solution (FLU-ACYL broncho) in clinical practice. Studies show that N-acetylcysteine is currently effective in the treatment of respiratory diseases due to its multicomponent effects on the respiratory system and the immune system. Hypertonic (3%) NaCl solution potentiates the action of N-acetylcysteine by inhalation and allows to achieve good results in the treatment of acute and chronic respiratory diseases in the optimal time.
One of the well-known in Ukraine products for fast and effective evacuation of viscous sputum is FLU-ACIL broncho, sterile solution for nebulizer and instillation. One 5 ml ampoule contains 300 mg of NAC, which has a mucolytic effect in direct contact with mucus, and 150 mg of hypertonic NaCl solution, which draws water from the intracellular space into the extracellular space by osmosis and increases the proportion of water in the bronchial secretion, dilutes it and thus facilitates its removal. The combination of NAC with hypertonic NaCl solution creates synergy and allows to obtain optimal treatment results with minimal side effects. This combination has mucolytic, anti-film, antiviral, antioxidant, anti-inflammatory and immunomodulatory effects, making it promising in a pandemic SARS-CoV-2.
No conflict of interests was declared by the authors.
References
Wei J, Pang CS, Han J, Yan H. (2019). Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis. Advances in therapy. 36 (12): 3356-3367. https://doi.org/10.1007/s12325-019-01111-4; PMid:31598901
Šalamon Š, Kramar B, Marolt TP et al. (2019). Medical and Dietary Uses of N-Acetylcysteine. Antioxidants (Basel, Switzerland). 8 (5): 111. https://doi.org/10.3390/antiox8050111; PMid:31035402 PMCid:PMC6562654
Chalumeau M, Duijvestijn YC. (2013). Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst. Rev. 5: CD003124. https://doi.org/10.1002/14651858.CD003124.pub4; PMid:23728642
Brodier EA, Raithatha M, Kannan S, Karunasekara N. (2020). Use of nebulised N-acetylcysteine as a life-saving mucolytic in intensive care: A case report. J Intensive Care Soc. 21 (4): 296-298. https://doi.org/10.1177/1751143719870089; PMid:34093730 PMCid:PMC8142091
Landini G, Di Maggio T, Sergio F, Docquier J-D, Rossolini GM, Pallecchi L. (2016). Effect of High N-Acetylcysteine Concentrations on Antibiotic Activity against a Large Collection of Respiratory Pathogens. Antimicrob Agents Chemother. 60 (12): 7513-7517. https://doi.org/10.1128/AAC.01334-16; PMid:27736757 PMCid:PMC5119039
Mata M, Sarrion I, Armengot M et al. (2012). Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. PLoS One. 7 (10): e48037-e48037. https://doi.org/10.1371/journal.pone.0048037; PMid:23118923 PMCid:PMC3485262
Samuni Y, Goldstein S, Dean OM, Berk M. (2013, Aug). The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 1830 (8): 4117-4129. https://doi.org/10.1016/j.bbagen.2013.04.016; PMid:23618697
Zinatullina KM, Orekhova AV, Kasaikina OT, Khrameeva NP, Berezin MP, Rusina IF. (2021). N-Acetylcysteine is an effective analog of glutathione in reactions with reactive oxygen species. Russ Chem Bull. 70 (10): 1934-1938. https://doi.org/10.1007/s11172-021-3299-8; PMid:34744411 PMCid:PMC8556857
Aldini G, Altomare A, Baron G et al. (2018). N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 52 (7): 751-762. https://doi.org/10.1080/10715762.2018.1468564; PMid:29742938
Poe FL, Corn J. (2020). N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med Hypotheses. 143: 109862. https://doi.org/10.1016/j.mehy.2020.109862; PMid:32504923 PMCid:PMC7261085
Blasi F, Page C, Rossolini GM et al. (2016). The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 117: 190-197. https://doi.org/10.1016/j.rmed.2016.06.015; PMid:27492531
Rasmussen K, Nikrad J, Reilly C, Li Y, Jones RS. (2016). N-Acetyl-l-cysteine effects on multi-species oral biofilm formation and bacterial ecology. Lett Appl Microbiol. 62 (1): 30-38. https://doi.org/10.1111/lam.12513; PMid:26518358 PMCid:PMC4715549
Marushko YuV, Hyshchak TV. (2016). Utvorennia bioplivok pry respiratornii patolohii. Vplyv ambroksolu na bioplivky dykhalnykh shliakhiv (ohliad literatury). Zdorove rebenka. 2: 88-94. https://doi.org/10.22141/2224-0551.2.70.2016.73816
Rodríguez-Beltrán J, Cabot G, Valencia EY et al. (2015). N-Acetylcysteine Selectively Antagonizes the Activity of Imipenem in Pseudomonas aeruginosa by an OprD-Mediated Mechanism. Antimicrob Agents Chemother. 59 (6): 3246-3251. https://doi.org/10.1128/AAC.00017-15; PMid:25801561 PMCid:PMC4432192
Domenech M, García E. (2017). N-Acetyl-L-Cysteine and Cysteamine as New Strategies against Mixed Biofilms of Nonencapsulated Streptococcus pneumoniae and Nontypeable Haemophilus influenzae. Antimicrob Agents Chemother. 61 (2): e01992-16. https://doi.org/10.1128/AAC.01992-16; PMid:27919900 PMCid:PMC5278723
Babić I, Baudoin T, Trotić R, Bedeković V. (2017). Therapeutic efficacy of azithromycin and acetylcysteine in chronic otitis media with effusion. Eur. Arch. Otorhinolaryngol. 274 (3): 1351-1356. https://doi.org/10.1007/s00405-016-4389-3; PMid:27873023
Mahakalkar SM, Nagrale D, Gaur S, Urade C, Murhar B, Turankar A. (2017). N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: a randomized, placebo-controlled, double-blinded study. Perspectives in Clinical Research. 8 (3): 132-136.
Jeeraaumponwat T. (2019). N-acetylcysteine and mortality in hospitalized pulmonary tuberculosis infection. European Respiratory Journal. 54 (63): PA2958. https://doi.org/10.1183/13993003.congress-2019.PA2958
Wong KK, Lee SWH, Kua KP. (2021). N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence. J Inflamm Res. 14: 2993-3013. https://doi.org/10.2147/JIR.S306849; PMid:34262324 PMCid:PMC8274825
Wu H, Song W, Gao X et al. (2014). Proteomics study of N-acetylcysteine response in H1N1-infected cells by using mass spectrometry. Rapid Commun Mass Spectrom. 28 (7): 741-749. https://doi.org/10.1002/rcm.6840; PMid:24573805
Zhang RH, Li CH, Wang CL, et al. (2014). N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury. Int Immunopharmacol. 22 (1): 1-8. https://doi.org/10.1016/j.intimp.2014.06.013; PMid:24968347 PMCid:PMC7106131
Scheffel MJ, Scurti G, Wyatt MM, Garrett-Mayer E, Paulos CM, Nishimura MI. (2018). N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. Cancer Immunol Immunother. 67: 691-702. https://doi.org/10.1007/s00262-018-2120-5; PMid:29396710 PMCid:PMC5862784
Shi Z, Puyo CA. (2020). N-Acetylcysteine to Combat COVID-19: An Evidence Review. Ther Clin Risk Manag. 16: 1047-1055. https://doi.org/10.2147/TCRM.S273700; PMid:33177829 PMCid:PMC7649937
Horowitz RI, Freeman PR, Bruzzese J. (2020). Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: a report of 2 cases. Respiratory Medicine Case Rep. 30: 101063. https://doi.org/10.1016/j.rmcr.2020.101063; PMid:32322478 PMCid:PMC7172740
Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. (2020). COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. In Vivo. 34 (3): 1567-1588. https://doi.org/10.21873/invivo.11946; PMid:32503814 PMCid:PMC8378025
Z hou N, Yang X, Huang A, Chen Z. (2021). The Potential Mechanism of N-acetylcysteine in Treating COVID-19. Curr Pharm Biotechnol. 22 (12): 1584-1590. https://doi.org/10.2174/1389201021999201228212043; PMid:33371832
De Flora S, Balansky R., La Maestra S. (2020). Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. The FASEB Journal. 34 (10): 13185-13193. https://doi.org/10.1096/fj.202001807; PMid:32780893 PMCid:PMC7436914
Jorge-Aarón RM, Rosa-Ester MP. (2020). N-acetylcysteine as a potential treatment for COVID-19. Future Microbiology. 15: 959-962. https://doi.org/10.2217/fmb-2020-0074; PMid:32662664 PMCid:PMC7359418
Singh P, Schwartz RA. (2020). Disseminated intravascular coagulation: a devastating systemic disorder of special concern with COVID-19. Dermatol Ther. 33 (6): e14053. https://doi.org/10.1111/dth.14053
George PM, Wells AU, Jenkins RG. (2020). Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 8 (8): 807-815. https://doi.org/10.1016/S2213-2600(20)30225-3; PMid:32422178
Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, Yarta K, Staniloae C, Williams M. (2020, Oct). Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol. 219: 108544. https://doi.org/10.1016/j.clim.2020.108544; PMid:32707089 PMCid:PMC7374140
Liu Y, Wang M, Liu G, et al. (2020). Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: a case report. Medicine. 99 (42): e22577. https://doi.org/10.1097/MD.0000000000022577; PMid:33080692 PMCid:PMC7571913
Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M et al. (2021). N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. Infect Dis (Lond). 53 (11): 847-854. https://doi.org/10.1080/23744235.2021.1945675; PMid:34182881
Taher A, Lashgari M, Sedighi L, Rahimi-Bashar F, Poorolajal J, Mehrpooya M. (2021). A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol Rep. 73 (6): 1650-1659. https://doi.org/10.1007/s43440-021-00296-2; PMid:34114174 PMCid:PMC8191712
Maffezzoni E, Notargiacomo M, Agostini S, Gelardi M. (2020). Efficacy of a nasal spray containing N-acetylcysteine in hypertonic solution in the treatment of nonallergic chronic rhinitis with goblet cell metaplasia. J Biol Regul Homeost Agents. 34 (6): 2345-2352.
Macchi A, Terranova P, Castelnuovo P. (2012). Recurrent acute rhinosinusitis: a single blind clinical study of N-acetylcysteine vs ambroxol associated to corticosteroid therapy. Int J Immunopathol Pharmacol. 25 (1): 207-217. https://doi.org/10.1177/039463201202500123; PMid:22507333
Kim D, Kim YH, Kwon S. (2018). Enhanced nasal drug delivery efficiency by increasing mechanical loading using hypergravity. Sci Rep. 8 (1): 168. https://doi.org/10.1038/s41598-017-18561-x; PMid:29317727 PMCid:PMC5760728
McCarthy SD, González HE, Higgins BD. (2020). Future Trends in Nebulized Therapies for Pulmonary Disease. Journal of Personalized Medicine. 10 (2): 37. https://doi.org/10.3390/jpm10020037; PMid:32397615 PMCid:PMC7354528
Dhanani J, Fraser JF, Chan HK, Rello J, Cohen J, Roberts JA. (2016). Fundamentals of aerosol therapy in critical care. Crit. Care. 20: 269. https://doi.org/10.1186/s13054-016-1448-5; PMid:27716346 PMCid:PMC5054555
Hagiwara SI, Ishii Y, Kitamura S. (2000). Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med. 162: 225-231. https://doi.org/10.1164/ajrccm.162.1.9903129; PMid:10903246
McGinn KA, Weigartz K, Lintner A, Scalese MJ, Kahn SA. (2019). Nebulized Heparin With N-Acetylcysteine and Albuterol Reduces Duration of Mechanical Ventilation in Patients With Inhalation Injury. J Pharm Pract. 32 (2): 163-166. https://doi.org/10.1177/0897190017747143; PMid:29233052
Otu A, Langridge P, Denning DW. (2018). Nebulised N-Acetylcysteine for Unresponsive Bronchial Obstruction in Allergic Brochopulmonary Aspergillosis: A Case Series and Review of the Literature. J. Fungi. 4: 117. https://doi.org/10.3390/jof4040117; PMid:30326585 PMCid:PMC6308940
Laguna TA, McNamara J, Zhang L, Demirel N. (2017). The effect of long term use of inhaled N-acetylcysteine on cystic fibrosis lung disease. C67. Suppurative Lung Diseases In Children: A6142. URL: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A6142.
Schauble AL, Bisaccia EJ, Lee G, Nazr SZ. (2019). N-acetylcysteine for management of distal intestinal obstruction syndrome. The Journal of Pediatric Pharmacology and Therapeutics: JPPT: The Official Journal of PPAG. 24 (5): 390-397. https://doi.org/10.5863/1551-6776-24.5.390; PMid:31598102 PMCid:PMC6782121
Bateman DN, Dear JW, Thanacoody HKR, et al. (2014). Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet. 383 (9918): 697-704. https://doi.org/10.1016/S0140-6736(13)62062-0; PMid:24290406
Daoud A, Dalhoff KP, Christensen MB, Bøgevig S, Petersen TS. (2020). Two-bag intravenous N-acetylcysteine, antihistamine pretreatment and high plasma paracetamol levels are associated with a lower incidence of anaphylactoid reactions to N-acetylcysteine. Clin Toxicol. 58 (7): 698-704. https://doi.org/10.1080/15563650.2019.1675886; PMid:31601129
Schwalfenberg GK. (2021). N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks). J Nutr Metab. 2021: 9949453. https://doi.org/10.1155/2021/9949453; PMid:34221501 PMCid:PMC8211525
Sansone RA, Sansone LA. (2011). Getting a knack for NAC: N-Acetyl-Cysteine. Innovations in Clinical Neuroscience. 8 (1): 10-14.
Masoompour SM, Anushiravani A, Tafaroj Norouz A. (2015). Evaluation of the Effect of Nebulized N-Acetylcysteine on Respiratory Secretions in Mechanically Ventilated Patients: Randomized Clinical Trial. Iran J Med Sci. 40 (4): 309-315.
Naz F, Raza AB, Ijaz I, Kazi MY. (2014). Effectiveness of nebulized N-acetylcysteine solution in children with acute bronchiolitis. Journal of College of Physicians and Surgeons Pakistan. 24 (6): 408-411.
Liu H, Wang W, Gao X. (2020). Comparison of the efficacy of ambroxol hydrochloride and N-acetylcysteine in the treatment of children with bronchopneumonia and their influence on prognosis. Exp Ther Med. 20 (6): 130. https://doi.org/10.3892/etm.2020.9260; PMid:33082862 PMCid:PMC7557708
Pogrebniak OO. (2016). Hipertonichnyi rozchyn natriiu khlorydu - prostyi ta efektyvnyi zasib u likuvanni osnovnykh zakhvoriuvan orhaniv dykhannia. Liky Ukrainy. 5-6 (201-202): 10-16. https://doi.org/10.37987/1997-9894.2016.5-6(201-2).204726
Heikkilä P, Korppi M. (2021). Hypertonic saline in bronchiolitis: an updated meta-analysis. Archives of disease in childhood. 106 (1): 102. https://doi.org/10.1136/archdischild-2020-319048; PMid:32213483
Huiberts A, Zweijpfenning S, Pennings LJ et al. (2019). Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary disease. Eur. Resp. J. 54 (1): 1802143. https://doi.org/10.1183/13993003.02143-2018; PMid:31000680
Wark P, McDonald VM. (2018). Nebulised hypertonic saline for cystic fibrosis. The Cochrane database of systematic reviews. 9 (9): CD001506. https://doi.org/10.1002/14651858.CD001506.pub4; PMid:30260472 PMCid:PMC6513595
Michon A-L, Jumas-Bilak E, Chiron R, Lamy B, Marchandin H. (2014). Advances toward the Elucidation of Hypertonic Saline Effects on Pseudomonas aeruginosa from Cystic Fibrosis Patients. PLoS ONE. 9 (2): e90164. https://doi.org/10.1371/journal.pone.0090164; PMid:24587256 PMCid:PMC3938589
Stathis C, Victoria N, Loomis K, Nguyen SA, Eggers M, Septimus E, Safdar N. (2021). Review of the use of nasal and oral antiseptics during a global pandemic. Future Microbiol. 16 (2): 119-130. https://doi.org/10.2217/fmb-2020-0286; PMid:33464122 PMCid:PMC7842245
Machado RRG, Glaser T, Araujo DB et al. (2021, Sep 3). Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial Cells. ACS Pharmacol Transl Sci. 4 (5): 1514-1527. https://doi.org/10.1021/acsptsci.1c00080; PMid:34651104 PMCid:PMC8442612
Kochuieva MM, Hrek II, Rohozhyn AV, Kochuiev HI. (2021). Zastosuvannia inhaliatsiinykh zasobiv dlia znyzhennia chastoty zahostren khronichnoho bronkhitu. Ukr. Med. Chasopys. 4 (144); VII/VIII: 2-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
